Inflammation Research

, Volume 60, Issue 7, pp 655–663

Prostaglandin I2 analogues suppress TNF-α expression in human monocytes via mitogen-activated protein kinase pathway

  • Wei-Li Wang
  • Chang-Hung Kuo
  • Yu-Te Chu
  • Ching-Hua Huang
  • Ka-Pan Lam
  • Shau-Ku Huang
  • Yuh-Jyh Jong
  • Yu-Ting Kuo
  • Chih-Hsing Hung
Original Research Paper

DOI: 10.1007/s00011-011-0317-6

Cite this article as:
Wang, W., Kuo, C., Chu, Y. et al. Inflamm. Res. (2011) 60: 655. doi:10.1007/s00011-011-0317-6

Abstract

Objective and design

Although treatment for asthma control has improved a lot recently, refractory asthma is still a challenge for clinicians. Evidence revealed that anti-tumor necrosis factor (TNF)-α therapy may have potential in treating refractory asthma. Recently in an animal model, prostaglandin I2 (PGI2) analogues can suppress the cardinal feature of asthma. However, whether PGI2 analogues can regulate TNF-α expression in monocytes and the mechanism is not well-known.

Materials and methods

The human monocytes were pretreated with beraprost, iloprost and treprostinil, three PGI2 analogues, before stimulation with lipopolysaccharide (LPS). TNF-α concentration of the cell supernatants was measured by ELISA. Intracellular signaling was investigated by Western blot.

Results

PGI2 analogues suppressed LPS-induced TNF-α expression in THP-1 cells. CAY10449, an I prostanoid receptor antagonist, could reverse these effects. Beraprost increased intracellular cAMP level in THP1 cells. Forskolin, an adenylyl cyclase activator, could confer similar effect. LPS-induced TNF-α expression in THP-1 cells could be reversed by mitogen-activator protein kinase (MAPK)-p38, extracellular signal-related kinase (ERK) and c-Jun N-terminal kinase (JNK) inhibitors. Western blot revealed that beraprost suppressed MAPK phospho-p38, phosphor-JNK and phosphor-ERK expression.

Conclusion

PGI2 analogues suppressed LPS-induced TNF-α expression in THP-1 cells via the IP receptor-cAMP and the MAPK pathways. PGI2 analogues may have potentiality to treat asthma.

Keywords

Tumor necrosis factor αI prostanoid receptorMAPK pathwayMonocytesProstaglandin I2

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  • Wei-Li Wang
    • 1
    • 2
  • Chang-Hung Kuo
    • 2
    • 3
    • 6
  • Yu-Te Chu
    • 2
  • Ching-Hua Huang
    • 8
  • Ka-Pan Lam
    • 4
  • Shau-Ku Huang
    • 9
  • Yuh-Jyh Jong
    • 2
    • 5
    • 6
  • Yu-Ting Kuo
    • 1
    • 2
  • Chih-Hsing Hung
    • 2
    • 3
    • 5
    • 6
    • 7
  1. 1.Department of Emergency MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  2. 2.Department of PediatricsKaohsiung Medical University HospitalKaohsiungTaiwan, ROC
  3. 3.Department of PediatricsKaohsiung Municipal Ta-Tung HospitalKaohsiungTaiwan
  4. 4.Department of PediatricsPingtung Christian HospitalPingtungTaiwan
  5. 5.Department of Pediatrics, Faculty of MedicineCollege of Medicine, Kaohsiung Medical UniversityKaohsiungTaiwan
  6. 6.Graduate Institute of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  7. 7.Center of Excellence for Environmental MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  8. 8.Department of PediatricsYuan’s General HospitalKaohsiungTaiwan
  9. 9.Johns Hopkins Asthma and Allergy CenterJohns Hopkins University School of MedicineBaltimoreUSA